Shire doubles sales on the back of Baxalta takeover

Short resume:

sales
80%
baxalta
60%
deal
50%
company
50%

Pharmaceuticals giant Shire is enjoying its Golidlocks phase after sales more than doubled in its first quarter following the $32bn (£24.7bn) takeover of haemophilia specialist Baxalta last year.
Source Telegraph.co.uk
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*